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The theme selection of the dissertation was motivated by my earlier work 
experiences. During my ministry work, I had a good impression about the 
situation of the Kazakh pharmaceutical industry. I met with a lot of experts 
and with a lot of data, so I could reasonably believe that an appropriate 
database could be built for a reliable statistical analysis. During my PhD 
training one quantitative methodology course made it clear to me, that the 
available and accessible Kazakh pharmaceutical industry’s data, relating to 
my topic, is unsuitable for a comprehensive statistical analysis. One reason 
for this is that the regular data collection in the Kazakh industry was 
subordinated to the needs of the Moscow center, therefore till 1990 only 
aggregated data was disclosed. The situation has changed since then, but the 
fast-moving economy has suffered from slow or rapid growth periods. The 
inflation rate is sometimes very high with two digits number, though 
sometimes much lower. As it is well known the Kazakh economy is very 
much dependent on the oil market. When the oil prices are high, our economy 
is growing fast, when it is lower our economy is slowing down. I could only 
create comparable time series if I had internal information about these 
processes. In the meantime, however, my relationship with the 
pharmaceutical sector was broken due to the scholarship. During my research 
activity, my interest also has changed. Although macroeconomic factors are 
playing an important role in the development of the pharmaceutical industry, 
external factors like oil prices are disturbing this picture so deeply, that it is 
almost impossible for an outsider, like myself, to separate the external factors 
from the internal ones. As I learned more and more in the PhD program, I had 
to realize that my original research questions moved far from me. A solid 
study based on statistics could be analyzed if there were adequate data, what 
is not the case. In the literature I have found more facts but less explanations 
or answers to my questions. Today I am more interested in what the reason 
is, why people - even the professionals - think about the so-called objective 
reality so differently. In the pharmaceutical and healthcare sector, I have also 
found that opinions are even more subtle, such as whether the patient can 
choose what drugs to take, or he must accept medications that are supported 
by health insurance? There are very different opinions about the advertising 
of medicines as well. There are some people who are very positive about 
advertisement, and there are others who are criticizing it because they are 
aware, that the advertisements are the main driving force behind the growth 
of the consumption of pharmaceuticals. During my research, it became clear 
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to me that I was more interested in subjective opinions. At the beginning of 
my research I was trying to rely on the so-called objective, professional 
opinions. The roots of my starting interest were my job experiences in my 
ministerial work. The second, not less important reason behind my new 
research orientation, that for a broad, rational questionnaire survey I did not 
have any financial resources, we had to look for a method that could be used 
with little financial resources and more personal involvement and could 
reliably prove my hypotheses. I chose the Q method at the advice of my 
supervisor Professor Sandor Kerekes.  
In the first chapter of the dissertation I work on the literature, which I group 
around four dilemmas. With regard to the pharmaceutical industry, each of 
the four dilemmas can be considered a research question. The first dilemma: 
Generic or original drugs? The second: Innovate or die? The third: Producing 
or importing the drugs? And the fourth: More marketing than R&D? Of 
course, we could not find clear answers to these questions, so I called these 
dilemmas. 
In the second chapter of the dissertation I analyzed the development of the 
pharmaceutical business between 2001 and 2017 based on the available 
statistical data. 
The accurate statistics are often missing so we have to estimate the 
expenditure on Marketing and Sales as well as on Research and Development. 
We tried to focus on those companies in Hungary and in Kazakhstan where 
the appropriate data were available. We cannot generalize the results, which 
are based on two companies, one representing Hungary, this is Richter 
Gedeon and the other is a Kazakhstan pharmaceutical company Chempharm. 
Beside the market statistics, we are considering the regulation differences 
among the countries with special attention to Hungary and Kazakhstan. 
Currently pharmaceutical companies are spending proportionally less on 
Research and Development year by year. The development of new drugs is a 
costly and time consuming process. The research activity of creating new 
drugs requires billions of dollars and the licensing process may take some 
decades. The shortest time frame is at least 10-15 years. Economic growth is 
especially important for countries such as Kazakhstan, where the standard of 
living is still very low, so the government should encourage it with many 
measures. Kazakhstan's pharmaceutical industry is focused on the domestic 
market to meet domestic demand for pharmaceutical products at the expense 
of domestic producers by attracting foreign investment.  
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In the second chapter of the dissertation I analyze the situation of the Kazakh 
pharmaceutical industry. I pay special attention to foreign investments and 
international relations of Kazakh industry. The analysis shows that 
Kazakhstan's participation in some international conventions helps to create 
a monopoly situation and restricts competition, which can lead to higher drug 
prices. 
In the third chapter I present the Q methodology used for empirical research, 
relying on the literature. Based on my own experience and the opinions of my 
former colleagues, I have tried to formulate statements that represent people's 
views on the pharmaceutical industry and healthcare in Kazakhstan. The Q 
methodology literature calls this concourse. Then I asked the opinion of 
twenty high-ranking intellectuals about the statements, and in the final part of 
the chapter I analyze the results and draw conclusions from them. 
In the fourth chapter, based on the experiences of previous analysis and 
empirical research, I deal with the current development problems and 
opportunities of the Kazakh pharmaceutical industry. 
 
The research questions and my hypotheses 
The hypotheses can be divided into two groups. The first group includes my 
hypotheses that deal with structural changes in the pharmaceutical industry 
and can be proved by objective statistical data: 
1. The sharpening competition should result in a price reduction. 
However, this is not the case in the pharmaceutical industry. Prices are rising 
due to increased marketing costs. Demand for industry products is increasing 
because people are increasingly willing to spend on their health. 
2. The cost structure of the pharmaceutical industry has changed. At 
the moment, marketing is the biggest cost factor, while Research and 
Development costs represented the biggest cost factor until the turn of the 
century. 
3. Some pharmaceutical companies specialize in generic medicines, 
which would justify a significant reduction in the cost of generic medicines, 
but this is not the case because most of the manufacturers are in a monopoly 
position in the markets concerned, partly due to drug regulation. The 
drugstore accepts certain import products, but not others. 
4. Convergence is an important condition for emerging economies. 
Professionals agree that only the economy that is present in high value-added 
industries is successful. In the pharmaceutical industry, this means that it 
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cannot be specialized solely in the production of generic drugs. Emerging 
economies must also spend on pharmaceutical research if, due to a lack of 
economies of scale, the production of organic medicines will not be 
profitable. This is innovate or die dilemma. 
5. The pharmaceutical industry is a strategic industry. Because of the 
security of the country, you cannot give up the ability to manufacture certain 
basic medicines. We cannot answer the question on the basis of economic 
considerations only to produce or import drugs. The country's security 
vulnerability is lower if at least the majority of generic medicines are 
produced by the local economy. 
The second group of hypotheses are phenomena that can be explained by 
subjective factors. My research questions were: 
1 What is the reason, why people - even the professionals - think about 
the so-called objective reality so differently? Why health-related public 
discourse is so diverse. Whether the patient can choose what drugs to take, or 
he must accept medications that are supported by health insurance?  
2 There are some people who are very positive about advertisement, 
and there are others who are criticizing it because they are aware, that the 
advertisements are the main driving force behind the growth of the 
consumption of pharmaceuticals. Why their opinion is so different? 
The Q method was used to reveal the opinions. According to my hypothesis, 
three main opinion centers can be distinguished: 
1. The group of intellectuals who have closer ties with the 
pharmaceutical sector because of their qualifications or current jobs will have 
almost the same opinion about the pharmaceutical industry and drug 
consumption.  
2. The second opinion group is made up of intellectuals and 
entrepreneurs who are only consumers in relation to drugs and their 
knowledge is influenced by their personal experiences with health care and 
possibly their knowledge acquired through the media. 
3.  I assumed that intellectuals, who spent longer period in higher 
education in the West, have been influenced by this, and it has a certain 
impact on their value judgment. I expect that their opinion is biased by the 





The development of the pharmaceutical industry in Hungary 
and in Kazakhstan between 2001-2017 
The pharmaceutical industry of Hungary is traditionally an important branch 
of the Hungarian economy. This sector is strongly export-oriented, and the 
only one which could maintain high R&D activities during the transition 
period, and only this was able to keep a relatively high investment level in the 
field of R&D. In Hungary the chemical and pharmaceutical industry is 
traditionally strong. This is because of the early specialization of the market 
during the Soviet period and the good tradition of the higher education in the 
field of chemistry. Some Hungarian chemists and physiologists got a Nobel 
prize for their discoveries, like Albert Szentgyorgyi 1937, Gyogy Hevesi 
1943, Gyorgy Bekesi1961, Janos Polanyi 1986, Janos Olah 1994. Although 
the majority of them got the Nobel prize not in Hungary, they studied or 
worked in Hungarian Universities in part of their life. Hungary invested a lot 
in this field for education and research. Organic and biochemistry is one of 
the success fields. Hungary has four medical universities and all of them are 
very successful even internationally. Chemical institutes at several Hungarian 
universities are equally important in developing new drugs. This creates a 
solid basis for the pharmaceutical industry to develop original drugs. 
 
FIGURE 1. DYNAMICS OF PRODUCTION AND EXPORTS OF PHARMACEUTICAL PRODUCTS 
OF HUNGARY BETWEEN 2001-2017 
Sources: (Hungarian Central Statistical Office, 2001-2017), (Trade statistics 
for international business development, 2001-2017). 
High rates of economic development of Hungary were largely achieved 
through foreign capital investments. Over the past 18 years all major 
pharmaceutical companies have been privatized. Large stake in Chinoin 
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(Sanofi-France), EGIS (Servier-France), Biogal (Teva-Israel) Human 
(Novopharma-Canada) was purchased by foreign drug manufacturers. 
Richter Gedeon was privatized through an international private placement on 
the Budapest stock exchange. 
It should be noted that in Hungary the market of pharmaceutical products is 
small, because of this the export takes a huge share of production. Hungary 
mostly exports pharmaceutical products to Europe, USA and CIS countries 
in the following areas: cardiological, psychoneurological, dermatological, 
gynecological, antifungal, antihistaminic, gastroenterological, and 
antiallergic and others.  
The Kazakhstan pharmaceutical industry is more focused on the domestic 
market to meet the domestic demand in pharmaceutical products through 
domestic producers by attracting foreign investment. This is a task related to 
the high import of medicines, which is 78% (in value terms). Pharmaceutical 
industry of Kazakhstan is divided into two categories of production: 1) 
manufacture of basic pharmaceutical products - 12 producers; 2) 
pharmaceutical preparations – 65 manufacturers. 
 
FIGURE 2. DYNAMICS OF PRODUCTION AND EXPORTS OF PHARMACEUTICAL PRODUCTS OF 
KAZAKHSTAN BETWEEN 2001-2017 YEARS 
Sources: (Committee on Statistics Ministry of National Economy of the 
Republic of Kazakhstan, 2018), (Trade statistics for international business 
development, 2001-2017). 
Kazakhstan's production of pharmaceutical products is not export oriented, 
but is gradually gaining momentum in 2017 having increased compared to 
the previous year and amounted to 32 million USD. Mostly exported to 
Switzerland, Kyrgyzstan and Russia, other medicines, veterinary vaccines 
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were sent to Russia and Kyrgyzstan for this period and clotting factors of 
blood of human origin were sent to Switzerland. Russia and Kyrgyzstan are 
the main export markets due to their geographical proximity to manufacturers 
of pharmaceutical products in Kazakhstan. The domestic pharmaceutical 
products are exported to other countries in small quantities. 
In 2016 the pharmaceutical market in Kazakhstan showed a positive growth 
dynamic in the national currency. In dollar terms, the indicator was less in 
comparison with 2015 due to the instability of the exchange rate (see Figure 
3 below). 
 
FIGURE 3. THE DYNAMICS OF THE GROWTH OF THE PHARMACEUTICAL MARKET FOR THE 
PERIOD 2011-2016 
Source: (Consulting Group "Vi-ORTIS", 2018). 
Pharmaceutical industry in Kazakhstan is heavily dependent on imports of 
pharmaceutical raw material (substances), equipment and packaging 
materials. The dominant position of generic drugs in the Kazakhstan market 
allegedly linked to the lack of conditions for the creation of innovative 
products. The bulk of the consumption drugs in Kazakhstan generic - about 
90%, and the market of original drugs is no more than 8-10%, so that the 
production of generic drugs is the most attractive for increasing the share of 
domestic producers.  
More than 80% of pharmaceutical products are produced in Shymkent and 




FIGURE 4. SHARES OF THE REGIONS OF THE REPUBLIC OF KAZAKHSTAN IN THE 
PRODUCTION OF PHARMACEUTICAL PRODUCTS, IN TERMS OF MONEY IN 2017 
Source: (Aequitas Law Firm, Healthcare, Medicine and Pharmaceuticals, 
2017). 
The main producers of pharmaceutical products are: Joint-stock company 
Chempharm-Santo - Polpharm merger with a major Polish pharmaceutical 
company Polpharm, Joint-stock company Almaty pharmaceutical factory - 
Nobel with the Turkish company Nobel, GlobalPharm - AbdiIbrachim joint 
production with the Turkish company AbdiIbrachim, Karaganda 
Pharmaceutical Complex with the Russian company Pharmstandart, 
KazPharm - Kelun in conjunction with the major Chinese company Kelun 
and other companies. 
 
In marketing costs Hungary is following the world trends, 
Kazakhstan is still «Lagging» behind  
The pharmaceutical industry is one of the most productive and profitable 
industrial sectors; however, the drug development process remains risky and 
expensive. Therefore, effective intellectual property protection is the key to 
maintain innovation for drug development (Kermani F & Bonacossa P, 2003). 
Most medical research is done in high-income countries: 12 countries 
concentrate 80% of research spending. Moreover, medical research financing 
has been moving towards the private sector. 
The role of Marketing, Sales and R&D expenditure is the most influencing 
one in the pharmaceutical industry. The other expenditures are stable, so we 
decided to study how much pharmaceutical companies spend for Marketing, 
sales and for R&D. In such circumstances, testing the relationship between 
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R&D expenditure and advertising costs with the profitability of the 
pharmaceutical market can be interesting (Acosta A & Ciapponi A, 2014). 
 
FIGURE 5. THE EXPENDITURE OF TOP 5 GLOBAL PHARMACEUTICAL COMPANIES FOR 
MARKETING, SALES AND FOR R&D IN BILLION USD IN 2000-2018 YEARS 
Sources: (The 2018 Global Innovation 1000 study, 2005-2018), ( Pfizer, 
Annual report, 2000), (Pfizer, Financial report, 2018), (Novartis, Financial 
report, 2000), (Novartis, Financial report, 2018), (Sanofi, Annual report, 
2000), (Sanofi, Financial report, 2018), (Roche, Financial report, 2000), 
(Roche, Financial report, 2018), (GlaxoSmithKline, Annual report , 2000), 
(GlaxoSmithKline, Financial report, 2018). 
Penetration of generic medicines is more successful in countries that permit 
(relatively) free pricing of medicines (Germany, United Kingdom) than in 
countries that have pricing regulation (Belgium, Italy, Spain). This is because 
countries that adhere to free market pricing generally have higher medicine 
prices, thereby facilitating market entry of generic medicines, and a higher 
price difference between originator and generic medicines (Bartosik M, 
2005). 
The situation is significantly different in many Central and Eastern European 
countries, where generics make up as much as 70% of all medicines 
prescribed in terms of volume, whilst in value terms generics represent only 
30% of pharmaceutical expenditure. Consequently, the availability of 
affordable generic medicines in these countries, many of which joined the EU 
on May 1st 2004, is actually a major budgetary factor in both the retail and 
hospital sectors (The role of generics in Europe, 2010). 
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To analyze the European generic markets it is important to understand the 
core nature of national regulations on pharmaceutical products. They reflect 
the overall underlying national attitudes towards the provisions and financing 
of healthcare. The national regulations operating in a given market determine 
the structure and the environment, in which generic manufacturers need to 
function, commercialize and compete (A review on the European generic 
pharmaceutical market, 2005). 
Generics make up the majority of the new countries’ products, accounting for 
60 percent of prescription volume in the Czech Republic, 70 percent in 
Hungary, and 77 percent in Poland. Branded generics are particularly popular, 
as they offer the dual benefits of lower prices and higher perceived quality. 
Because of the evolution of patent law, the «generics» category often includes 
products that are patented elsewhere (Clark T, 2004). 
To understand the role of R&D in the pharmaceutical industry we have to 
compare it with other industries. We see in Figure 5 first is Pharmaceutical 
spent 180 billion USD on R&D in 2018, which was 90 billion USD in 2005. 
Computing and Electronics 170 billion USD in 2018 that shows an increase 
from 120 billion USD was spent in 2005. Also Software and Internet 165 
billion USD was spent in 2018 and in 2005 it was 30 billion USD. Auto 
industry spent 130 billion USD in 2018 and 70 billion USD in 2005. In 2018 
Industrials spent 90 billion USD and 40 billion USD in 2005. In the last 
thirteen years there are changes but Pharmaceutical is the first most research 
concentrated in the world and second is Computing and Electronics (See 
Figure 6). 
 
FIGURE 6. THE EXPENDITURE ON R&D BY INDUSTRY IN BILLION USD  




Figure 7. below shows the changes in the Marketing, Sales and R&D costs at 
Richter Gedeon pharmaceutical company between 2000-2015 years. As we 
see in Diagram 1 in 2015 Richter Gedeon spent nine times more on Marketing 
and six times more on R&D than in the year 2000, therefore the expenditure 
on marketing grew much faster than the expenditure on R&D, which is in 
harmony with the world trends. 
 
FIGURE 7. CHANGES IN MARKETING AND R&D COSTS AT RICHTER GEDEON 
PHARMACEUTICAL COMPANY IN MILLION HUF BETWEEN 2000-2015 YEARS 
Source: (Richter Gedeon Delivering quality therapy since 1901, Annual 
Report, 2000-2015). 
 
Richter Gedeon is the leader among the independent Hungarian 
pharmaceutical companies in investment in research, their share in the total 
turnover is almost 10%, which in absolute terms puts the company in the 1st 
place concerning the level of expenditure on R&D in the country and in 
Central and Eastern Europe as well (Report Hungary 
Pharmaceuticals&Healthcare, 2015). 
The pharmaceutical companies spend €4.0 million on advertisements in 
medical journals in Hungary. The total amount spent by pharmaceutical 
companies on product advertisements in the 115 Hungarian printed medical 
journals came to almost 1.2 billion HUF in 2015 (€4 million), Comfit, a media 
monitoring company, which specializes in medical journals, revealed it to 
Central Europe Pharma News. The same companies spend 478.7 million HUF 
(€1.6 million) on advertising the companies themselves (not their products). 
Richter Gedeon led the field in terms of advertising expenditure, with a figure 
of 90.4 million HUF (€303000). In the second place there were Egis and 
Woerwag Pharma (Central Europe Pharma News Issue, 2013).  
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The pharmaceutical market of Kazakhstan was estimated at 950 million USD 
in 2016, the market is divided into retail pharmacy sales and government 
procurement. Out of these domestic productions of pharmaceutical products 
occupies only 22%. The main parts of the product portfolios of domestic 
manufacturers are low-profit generic drugs (share in the total market volume 
is 90%) and the market of the original drugs is 10%, which allows 
pharmaceutical manufacturers to allocate their profits on R&D of new 
original drugs. 
The biggest Kazakhstan pharmaceutical company ChemPharm-Santo 
specialized in generic drugs spends much less on marketing than on 
production of generic drugs. Diagram 6 shows how the pharmaceutical 
company ChemPharm-Santo spends a very small share of its revenue of 15.1 
million KZT on marketing. The production of generic drugs in 2015 produced 
733.3 million KZT, however, in 2000 it produced more than 843 million KZT. 
 
FIGURE 8. THE EXPENDITURE ON GENERIC DRUGS AND ON MARKETING OF THE 
PHARMACEUTICAL COMPANY CHEMPHARM OF KAZAKHSTAN IN MILLION KZT BETWEEN 
2000-2015 YEARS 
Sources: (Santo Member of Polpharma Group, Annual report, 2000), (Santo 
Member of Polpharma Group, Annual report, 2015). 
 
Foreign pharmaceutical companies in Kazakhstan spend about 10-15% of 
annual turnover on marketing programs to introduce their products to doctors, 
including sponsoring a conference participation and publication. In the over-
the-counter segment where direct advertising of medicines for consumers is 
allowed, foreign manufacturers also managed to increase their market share. 
Foreign pharmaceuticals increased their market share thanks to advertising, 
despite the fact that domestic medicines were cheaper, but they were not 
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properly advertised. In Kazakhstan imported branded generics and innovative 
drugs are very popular among physicians, and pharmacy staff often 
recommend patients who they cured. 
The regulation of advertising and promotion of pharmaceutical products in 
the United States of America, Europe, Hungary and Kazakhstan. I consider 
how each country regulates the advertising of pharmaceutical products. In the 
United States marketing and distribution of pharmaceuticals is heavily 
regulated by the federal Prescription Drug Marketing Act.  
In general, pharmaceutical companies adhere to FDA regulatory guidelines 
that require all DTC ads and information to be accurate in order to provide 
substantive evidence of any statements that have been made, to strike a 
balance between the risks and benefits of the product being promoted and to 
maintain consistency with the labeling approved by the FDA (U.S. Food and 
Drug Administration, FDA, 2017). Europeans still have quite limited 
exposure to pharmaceutical advertisements for prescription drugs. The EU is 
of particular attraction to pharmaceutical companies, however, as it accounts 
for a full one-third of global drug sales. In Europe, the advertising is regulated 
by the International Federation of the Pharmaceutical Industry Manufacturers 
and Associations (Eagle L & Kitchen P, 2002). 
Methods used for empirical analysis 
From the point of view of my dissertation, the Q method is just a tool. It is 
not my task to develop further the Q methodology itself. I want to use the Q 
methodology for cognition of Kazakh pharmaceutical industry and Kazakh 
drug-related opinions. The method makes it possible to understand the 
structure of opinions and views on the manufacture and use of the drugs as 
well as the relationship between the different views about these topics. In the 
Q method, all of the opinions and views about the topic are called 
«concourse». «In Q, the flow of communicability surrounding any topic is 
referred to as a concourse (from the Latin concourses, meaning all running 
together», as when ideas run together in thought). 
In my case, considering the mathematical assumptions of the factor analysis 
methodology, and the experience of the Q method, we need about forty 
statements that meet the requirements of the method and adequately represent 
the concourse of the problem under examination. Of the seventy statements, 
we could have missed a lot because they were the ones that were in complete 
agreement with the ad hoc groups in which the relevance of the claims was 
tested. We left some statements out because the interpretation also caused 
problems for the panel during the discussions. 
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The steps of investigation in the Q method: 
 
FIGURE 9. THE STAGES OF Q METHOD 
 
Revealing the Kazakh pharmaceutical concourse and creating the 
statements 
In my case, formulation of the concourse was not a simple task. During the 
years I spent working in the pharmaceutical department in a senior position, 
I learned the opinions of a number of experts. It became apparent from the 
friends' inquiries, that the so-called ordinary man rarely meets the opinions of 
professionals. Concourses are considered appropriate if they represent the 
opinion of the multitude of people involved and if they are able to reveal the 
different clusters of views and the differences among them. 
In the first round, we made almost seventy statements partly based on our 
own experiences, partly based on the experience found in the literature and 
based on research on the health sector of using the Q method. Considering the 
selection of respondents, I could expect about twenty respondents who are 
expected to conscientiously evaluate the allegations. 
The 39 statements were translated into Russian and had been distributed 
among the cells by each of the individuals in the following triangle. This 
procedure is called: Q sorting. I could have used a variety of triangles, but 
this would not significantly affect our results, as can be seen from the 
following quote:  
The 39 statements, according to the logic of Q method, in order to provide a 
discrete normal distribution, sample members had to position 39 squares of 
the following triangle below. 
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The distribution among the cells took 30 to 45 minutes for each participant. 
At first, they were averse to the task. Many people have challenged us, why 
the method narrows their choices into this framework.  
At first, many people had problems with why there could be no more than 
two of the total agreements or the total number of denied claims. Later, they 
were reconciled to the task and after about 10 minutes they went into the task 
and later, several people said they considered it a challenge and, finally, they 
were particularly interested in stumbling on statements and placing them in 
the appropriate cell. The members of the group solved the task one  
by one within a three-week time interval when I personally visited the group 
members and with some of them managed to make a structured interview, 
which is described in the evaluation part of my dissertation. 
1. The pharmaceutical industry spends an unreasonably lot of money for advertisement of drugs. 
2. Pharmaceutical advertisement is very useful because the consumers are getting very useful information through it about new 
drugs. 
3. Most doctors prescribe conventional and well-known drugs. 
4. It would be desirable to monitor the R&D activities of pharmaceutical companies more closely. 
5. The price of medicines should be determined by the state. 
6. It is advisable to keep the medicines for acute diseases at a persistently low level. 
7. People are consuming unnecessarily many medications. It would be reasonable to sell the drug for medical prescription only. 
8. The pharmaceutical industry is one of the most profitable industries. For international firms the profit is more important than the 
healing of diseases. 
9. The pharmaceutical industry should operate based on the same ethical principles, like the doctors. The profit is secondary. 
10. The income of doctors largely depends on their relationship with the pharmaceutical industry, this undermine the credibility of 
the doctors. 
11. The drug consumption is unjustifiably high. 
12. The aim of marketing is to know and understand the customer so well the product or service fits him and sells itself.  
13. Understanding patient behaviour is essential to influencing them. 
14. Models of consumer behaviour can help pharmacists increase medication adherence, change smoking behaviour, communicate 
health messages, design services, and influence physician prescribing. 
15. Some patients have more diseases and they get treatment for them. Used drugs interact. We need independent research to study 
this issue. 
16. The pharmacy store should be an intimate private area where the consumer and the pharmacist can discuss how the consumer 
should use her/his medicines. 
17. The customers can use the competence of the pharmacists as support, when they decide what drugs to take, and when to take 
them. 
18. The pharmacist should make a thorough professional review of each drugs bought by the consumer.  
19. The pharmacist should confirm to the consumer that the chosen drug is safe for use. 
20. The pharmacy should be like a health marketplace, where consumers can get drugs, lifestyle advice, blood pressure measurements 
or whatever they need. 
21. The pharmacy I leave with good questions for the physician visit when I have discussed my drug use with the pharmacist. 
22. The pharmacist knows the medicine better than the physician, so it is advisable to ask him before the prescription of the 
medication. 
23. The pharmacist’s connections with the physicians make it 100% certain that everybody get the right drug on. 
24. When a consumer has questions about his/her drugs, the pharmacist should answer them. 
25. Each drug has side effects, to use them for medication is based on the patient’s assessment of risks versus benefits. 
26. The use of a drug is enough a belief that the disease will get better with treatment. 
27. The protection of intellectual property is a barrier to scientific progress. If world scientists could make their findings public, they 
would have solved a few diseases. 
28. From a business interest, they also buy patents that they do not want to use. This slows down scientific progress. 
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29. Most of the innovations are not born today because explorers "want to make the world better", but from business interests or 
research fame. 
30. Research across the world of pharmaceuticals with minimal coordination would be enough to treat illnesses that affect only few 
people or poor people. 
31. The branded drugs in the world are much more expensive than the quality difference justifies. The success of the drug is largely 
based on marketing. 
32. A researcher, when he discovers a new drug, is best sold to his patent to world business. 
33. In the pharmaceutical industry, research and licensing costs are so high that small-scale small companies can maintain a 
meaningless research laboratory. 
34. Newer pharmaceutical companies are trying unnecessarily with research, and market success cannot be achieved. 
35. In all countries it is advisable to maintain laboratories for pharmaceutical research, not because they could expect economic 
results, but because without that, the country would still be unable to follow the development of world science. 
36. There are some types of drugs that are used to treat the most important for life, but with the quality of life ethically questionable. 
37. People trust local pharmaceutical drugs because of their quality-price ratio. 
38. The quality of pharmaceutical drugs satisfies the need of local consumers. 
39. In Kazakhstan, Ukrainian, Russian and Belarusian medicines are more recognizable than medicines from Europe and the USA. 
 
 
FIGURE 10. THE FORCED‐DISTRIBUTION Q SORTS TRIANGLE FOR 39 STATEMENTS 
In my investigation the P set were created from twenty respondents who 
formed a heterogeneous group. All of them are graduates of universities, 
some of them have graduated abroad. Some have established their own 
companies or leading industrial companies. Significantly public employees 
were involved among the respondents, which obviously influenced their 
opinion.  
The selection of the sample, despite some inconsistencies, followed the logic 
of wanting to find out whether those who are in close contact with the 
pharmaceutical industry because of their day-to-day work because they are in 
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such companies or they may be working in a pharmacy or knowing about 
their work through healthcare, and how do the so-called non-professional 
opinions differ and how do they match the opinions of professionals? It was 
an exciting question to see whether the foreign studies, already developed in 
market economies, have an impact on foreign studies. 
The 20 persons, although they form a heterogeneous group, can be divided 
into three groups with respect to their values. According to my hypothesis, 
the intellectuals who have closer ties with the pharmaceutical sector because 
of their qualifications or current jobs will have almost the same opinion about 
the pharmaceutical industry and drug consumption. The other opinion group 
is made up of intellectuals and entrepreneurs who are only consumers in 
relation to drugs and their knowledge is influenced by their personal 
experiences with health care and possibly their knowledge acquired through 
the media. In my hypothesis, I also assumed that intellectuals, who spent 
longer period in higher education in the West, have been influenced by this, 
and it has a certain impact on their value judgment. I expect that their opinion 
is biased by the impact of the «consumer society» and the knowledge of the 
western pharmaceutical market. 
 
 
FIGURE 11. THE FACTORS 
When exploring concourse, we began by considering that there was a 
significant difference in opinion among respondents about their relationship 
with the pharmaceutical sector. People - and in this respect Kazakh are no 
exception - tend to think in stereotypes. With regard to the pharmaceutical 
industry, such a stereotype may be that drugs are expensive because they 
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come from imports. Others say that the main reason for this is that they spend 
too much on advertising in the pharmaceutical industry and do not spend 
enough on drug research. According to other stereotypes, it is unnecessary for 
a small economy to develop its own pharmaceutical industry, because the 
research of original drugs is only rewarding for multinational companies with 
a strong capital. In developing countries, there is a relatively widespread view 
that, without their own research and development institution, it is impossible 
to catch up with the developed regions. Therefore, the pharmaceutical 
industry needs to be developed even if it does not seem economically rational. 
The state must definitely regulate and support the pharmaceutical industry. 
The 39 statements made should represent this diverse picture in a 
representative way. We hoped that the 20 people interviewed would express 
their opinions and identify certain types of opinions. At the start, we expected 
to be able to identify at least three types, and we assumed that each type would 
be related to the person's qualification or job. 
 
The result of the factor analysis 
When we dealt with the types of opinions, exploring the concourse, we were 
expecting three types. At the end of the analysis, the following three types 
were identified based on the Q method: 
1. type Positively biased pharma-experts (Committed Pharmacists) 
They form a center of opinion and agree that doctors tend to prescribe only 
the medicines they know, who consider the pharmaceutical industry to be a 
very profitable industry, and who think foreign manufacturers are too profit 
oriented. Their professional commitment is also reflected in the fact that 
pharmacists are highly respected. Pharmacists believe that they should also 
perform other services for the benefit of society. 
2. type Some scepticism against the pharma sector (Doubt about the 
medical sector). They are engineers, economists or language teachers 
according to their qualifications. One of them was originally a chemical 
engineer, this qualification is professionally close to the pharmaceutical 
industry. One of them a financial economist who now works as a project 
manager and is therefore reasonably skeptical about the pharmaceutical 
potential of a relatively small economy. for Kazakhstan it does not seem 
appropriate to produce medicines that require serious research, production 
and distribution. This may be good in other countries. At the same time, 
Kazakhstan should still produce medicines that are the easiest to manufacture 
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and can be consumed both in the domestic market and exported to other 
countries. 
In this regard, each country is unprofitable to produce all the drugs and 
Kazakhstan is recommended to find its niche in world trade. 
3. type Marketed and/or socialized health care (Marketizing the 
pharmaceutical sector) «Marketed and/or socialized health care» is a mixed 
type, with sometimes contradiction viewpoints. This type is represented by 
two persons: Dinara and Zhanibek, both of them working as leader and they 
studied earlier in the West. In the one hand this type is very much market 
oriented, some of their values are similar to those who are living in advanced 
market economies. This type tries to reconcile contradictory opinions. On the 
one hand, they affirm the market economy, on the other hand, they also 
consider the ethical and welfare aspects to be important in the day-to-day 
operation of the health sector. They are clearly open to accepting «western» 
culture and values, which are largely individualistic and market values, (but 
at the same time affirm the «caring» institutional system the profit is 
secondary. 7. People are consuming unnecessarily many medications, it 
would be reasonable to sell the drug for medical prescription only. 27. The 
protection of intellectual property is a barrier to scientific progress, if world 
scientists could make their findings public, they would have solved several 
diseases.). 
Risks affecting the development of the pharmaceutical 
industry of Kazakhstan, the problem is the economy of scale 
or more 
In comparison with world costs, the volume of investments in this sphere is 
much lower. At the same time, the process of developing medicines takes an 
average of 10-15 years, which makes the pharmaceutical industry quite 
knowledge-intensive. The emergence of new drugs involves the passage of 
long, long and costly clinical trials. In addition, not all domestic 
manufacturers of pharmaceutical products have modern technologies to 
produce original drugs from testing and production of new drugs to their 
introduction. 
Administrative barriers, which include complex procedures for laboratory 
analysis, lengthy consideration of registration of medicines, procedures for 
multiple re-registration (up to 6 months) of drugs also adversely affect the 
development of the industry. Domestic producers can incur tangible losses as 
a result of going through lengthy administrative procedures. 
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The imperfection of the post-registration monitoring system for the safety and 
efficacy of medicines is noted on the market of medicines. Consequently, in 
clinical practice, when deciding on the use of medicines, there is insufficient 
data on the safety and efficacy of the drugs. 
In the Republic of Kazakhstan for several years, the introduction of 
international standards GXP in the pharmaceutical industry of Kazakhstan is 
an actual direction. The need for innovation is not in doubt, and the 
requirements for the transition to GXP standards by 2018 are legally 
enshrined in the Code of the Republic of Kazakhstan «On the Health of the 
People and the Health System». Thus, the implementation of the international 
standard GPP (good pharmacy practice) will help improve the quality of 
drugs. However, there are risks of reducing competition and access to drugs 
by reducing the number of pharmacies. The risk to a greater extent may be 
provided by pharmacy institutions located in rural areas. 
One of the limiting factors in the development of the pharmaceutical industry 
is the high demand for qualified personnel. In the market there is an 
insufficient level of professional training and a shortage of qualified 
personnel. To improve the skills of new employees, companies at their own 
expense conduct training and internships.  
The discipline of clinical pharmacology is rapidly developing on the world 
pharmaceutical market. Clinical pharmacology studies various problems of 
drug therapy - the methodology of clinical trials, the metabolism of drugs, 
molecular pharmacogenetics, the analysis of drug intake, etc. The main 
direction of this discipline as a specialty is the study of questions concerning 
the health of patients. Specialists working in this field are trying to narrow the 
gap between drug manufacturers and clinicians. At present, there are about 
200 clinical pharmacologists in Kazakhstan, of which only 5% are graduates, 
the rest have certificates. Moreover, there is no status of clinical 
pharmacologists, regulatory legal acts, quotas for training in the specialty of 
«clinical pharmacology». 
In the portfolio of domestic pharmaceutical manufacturers there are obsolete 
and low-profitable generic drugs, which prevents the provision of the 
population with domestic products that meet international standards and 
technical regulations. Thus, in the pharmaceutical market of Kazakhstan there 
is a problem of poor quality of medicines. 
The backwardness of domestic technologies for the production of medicines 
does not allow import substitution of medicines. Domestic production is 
unable to completely cover the needs of the Kazakhstani pharmaceutical 
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market with medicines on the main pharmacotherapeutic groups (the share of 
domestic drugs is 10%). Under the existing conditions, the import substitution 
process will be lengthy due to administrative barriers (changes in the legal 
framework are required), lack of financing for the re-equipment of production 
facilities, and updating of the pharmaceutical portfolio. On average, the 
modernization of production takes 3-4 years. In the process of reconstruction, 
it is also necessary to maintain the existing production process, train the 
personnel, switch over to the assortment. 
Another problem in the domestic market is the lack of own innovative drugs. 
Kazakhstan is the country of release, mainly of generic drugs. The most of 
domestic producers' products consists of low-margin medicines, which 
prevents the allocation of the required amount from the proceeds for R&D. 
In Kazakhstan, there is a decline in the clinical trials market. So, in 2015, only 
12 clinical trials were conducted, which is 3 times lower than in 2014. All 
clinical trials were conducted only by domestic manufacturers. The decrease 
is due to the obsolete regulatory framework, as the Rules for the conduct of 
clinical trials and (or) trials of pharmacological and medicinal products, 
medical devices and medical equipment were approved in November 2009. 
The main barriers for attracting international clinical research to Kazakhstan 
include insufficient experience of the country's participation in clinical 
research; absence of a register of clinical studies conducted in Kazakhstan; 
insufficient number of medical institutions for conducting clinical trials, since 
mainly clinical research is carried out by universities and research institutes; 
insufficient number of experienced researchers. Insufficient number of 
research institutions reduces the country's attractiveness for conducting 
clinical trials. Terms for the approval of clinical trials, which are 120-160 
days are a barrier to the participation of Kazakhstani medical institutions in 
international clinical trials. In addition, there is no regulatory procedure in 
Kazakhstan that regulates the importation of equipment and medical devices 
for clinical trials. 
Conducting international clinical research affects the development of medical 
science in terms of improving the level of skills of medical personnel, transfer 
of advanced technology. The sponsor of the Clinical Research provides 
equipment, which is then donated to the clinic for free. Thus, the conduct of 
clinical research can become a locomotive for the development of medicine. 
The main barriers to conducting clinical trials in the Republic of Kazakhstan 
are the incompatibility of medical organizations with the criteria for 
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accreditation for conducting clinical trials, as well as the shortage of qualified 
specialists with GCP certificates. 
The aim is a theoretical review of the export and import of pharmaceutical 
products. We studied the dynamics of export and import of pharmaceutical 
products from Kazakhstan and Hungary between sixteen years. Calculations 
of exports and imports of pharmaceutical products per capita compared with 
GDP per capita in Kazakhstan and Hungary for the period 2001-2018. 
Priorities for the development of the Hungarian pharmaceutical industry and 
export orientation have been determined, than on the domestic market, also 
the development strategy for the pharmaceutical industry in Kazakhstan, 
which is oriented to the domestic market with a small share of exports. 
In recent years the trade and economic relations between Hungary and 
Kazakhstan has developed successfully in such areas as energy, food, 
pharmaceuticals, engineering, education and tourism. Kazakhstan is the third 
partner in the trade turnover of Hungary after Russia and Ukraine, despite the 
geographical distance of the two countries. 
The aim of the research is to show the effect of the pharmaceutical export on 
the economic growth of Hungary and of Kazakhstan between 2001–2017 
years. Any national economy in its development strives to achieve economic 
growth to increase the pace of growth of gross domestic product per capita. 
The economic growth especially important for countries as Kazakhstan where 
the living standard is still very low, so the government should stimulate it 
with many measures.  
The expenditure for Marketing, Sales and R&D of pharmaceutical products 
in Hungary. Among the independent Hungarian pharmaceutical companies 
Richter Gedeon is a leader in investment in research, their share in the total 
turnover is almost 10%, which in absolute terms puts the company in the 1st 
place concerning the level of expenditure on R&D in the country and in 
Central and Eastern Europe as well. 
The Expenditure on generic drugs and on Marketing of pharmaceutical 
products in Kazakhstan. The biggest Kazakhstan pharmaceutical company 
ChemPharm specialized in generic drugs spends much less on marketing than 
on production of generic drugs. Foreign pharmaceutical companies in 
Kazakhstan spend about 10-15% of annual turnover on marketing programs 
to introduce doctors their products, including sponsoring a conference and 
publication. In the over-the-counter segment where direct advertising of 
medicines for consumers is allowed, foreign manufacturers also managed to 
increase their market share. Foreign pharmaceuticals increased their market 
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share thanks to advertising, despite the fact that domestic medicines were 
cheaper but they were not properly advertised. In Kazakhstan imported 
branded generics and innovative drugs are very popular among physicians 
and pharmacy staffs often recommend patients who they cured. 
Sources of data include the Tech&Innovation, 2005-2018, Strategy&pwc, 
The 2018 Global Innovation 1000 study, 2005-2018: Top 20 Research and 
Development Spenders 2005-2018, Annual reports of pharmaceutical 
companies 2000-2018, Hungarian Central Statistical Office, Market of 
pharmaceutical products in Hungary, Committee on Statistics Ministry of 
National Economy of the Republic of Kazakhstan, Trade statistics for 
international business development, Teaching the Q Method in a class on 
urban sustainability, Richter Gedeon Delivering quality therapy since 1901, 
Annual Report 2000-2015, Report Hungary Pharmaceuticals&Healthcare -
2015, Santo Member of Polpharma Group, Annual report-2000, Santo 
Member of Polpharma Group, Annual report-2015. 
Recommendations and conclusions  
The possibility of creating an innovative base of pharmaceutical enterprises 
can be a gradual transition from the production of simple generic drugs to 
more complex ones. At the moment, the CIS countries have their own generic 
productions. For this reason, further expansion of Kazakhstani exports to the 
CIS countries will be conditioned by the capabilities of domestic producers 
to offer competitive innovative products or analogs of unique complex drugs. 
The innovative potential of Kazakhstan pharmaceutical enterprises directly 
depends on the provision of state support and the creation of an innovative 
climate. In order to further obtain technological and personnel competencies 
in the production of innovative drugs, it is necessary to attract leaders of the 
pharmaceutical market. The interest of foreign investors is due to the 
availability of storage facilities at the Kazakh side, as well as the 
infrastructure. As part of the development of the domestic pharmaceutical 
market, it is necessary to improve the registration of undesirable side effects 
of drugs in identifying serious or unforeseen adverse reactions with the 
decomposition of the list of reimbursable medicines. To introduce new 
qualifications for the pharmaceutical industry, cooperation between higher 
education institutions and pharmaceutical enterprises should be strengthened. 
In this regard, it is necessary to create a platform for discussing topical issues 
and problems in the field of education, which can reduce the existing gap 
between the education received and the real needs of pharmaceutical 
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enterprises. Thus, educational programs should be taught in accordance with 
GMP standards, which would further facilitate the work of the pharmaceutical 
complex after the introduction of the international standard of GMP and in 
the future would allow the creation of competitive production.  
To achieve high production of pharmaceutical products, it is necessary to 
increase the level of state support for the industry. Measures should be 
envisaged for producers of domestic pharmaceutical products: 
- receiving loans guaranteed by the government with a deferred payment and 
partial reimbursement of the loan from the republican budget; 
- financial support from the state when registering domestic drugs abroad, 
buying licenses and raw materials; 
- exemption from payment of import customs duties on equipment necessary 
for the investment project; 
- development of mechanisms for the inclusion in the existing long-term 
contracts of new, innovative medicines produced by domestic producers that 
have evidence-based medical effectiveness; 
- development of a mechanism for redistributing the supply of drugs between 
domestic producers, in case of failure to fulfill the declared obligations under 
long-term contracts; 
- strengthening the position of domestic pharmaceutical companies by 
stabilizing existing measures of state support (primarily in the framework of 
the state order); 
- development of new mechanisms to stimulate investment in the 
pharmaceutical industry, which should create conditions for a new qualitative 
growth in domestic production of pharmaceutical products in the long run; 
- monitoring of new categories of diseases that tend to spread in Kazakhstan, 
as well as in other countries; 
- establishment of centers for the development of new medicines for the 
planned import substitution of medicines; 
- approval of specialties for the development and production of medicines in 
higher and specialized educational institutions, as well as training specialists 
considering international standards of GMP. 
In addition, it is necessary to maintain the level of purchased pharmaceuticals 
within the guaranteed volume of free medical care because of their great 
social importance. From the state side, it is necessary to provide support to 
domestic pharmaceutical enterprises in the form of preferences and benefits. 
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New scientific results 
1. Numerous analyses have been conducted for both the Hungarian and 
Kazakh pharmaceutical industries. These analyses also include international 
comparisons. My analysis is specific because it compares the pharmaceutical 
industry of two countries that used to belong to Comecon Countries. Despite 
differences in population and level of development, it can be concluded that 
this comparison is more instructive for Kazakhstan than if I compared 
Kazakhstan's pharmaceutical industry with more advanced European 
countries, such as Denmark’s or the Switzerland’s pharmaceutical industry. 
Based on this comparison I could define my recommendations for the 
government. 
2. The pharmaceutical industry is still one of the most research-
intensive sectors today. And indeed, it is. In the business world and in the 
pharmaceutical industry in particular, it is considered natural and widely 
accepted that marketing costs have risen much faster than research costs over 
the past few decades. Because of the high marketing costs, pharmaceutical 
prices are high, so drugs are not accessible to the poor. Advertisements cause 
unreasonable drug consumption, which, in addition to health hazards, makes 
it impossible for the drug store to function effectively. Pharmaceutical prices 
are factors determining human well-being. The drug marketing in Kazakhstan 
is now emerging. It should be brought to the attention of the authority that 
this area should also be regulated. One of the scientific results of this 
dissertation is this early warning. 
We recommend the Governments and the International institutions to 
implement means which drive the pharmaceutical companies back to 
research. The governments should set limits for the advertisement in this 
field. They have to promote the open and the crowdsourcing innovations to 
make this kind of public good affordable for the poor as well. 
3. The Q method is widely used in the world to explore the attitudes of 
the consumers. The method helps to structure development ideas of industrial 
sectors. I think it is a new result of my own research, that despite the cultural 
differences, the method can be applied without difficulty for revealing the 
drug-related concourse of Kazakh people. Neither the statements nor the 
results differ from those used in international practice. 
I consider it a new scientific result that Kazakh intellectuals, who are having 
mainly technical and economic background, can be classified into three 
opinion types: 1. Positively biased pharma-experts; 2. Some scepticism 
against the pharmaceutical sector (Doubt about the medical sector). 3. 
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Marketed and/or socialized health care (Marketizing the pharmaceutical 
sector) The existence of these main types is proved by my own practical 
experience and the structured deep interviews presented in the dissertation as 
well. The types are extensively described in the dissertation and in the theses 
above. 
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